Washington, DC - District of Columbia Attorney General Karl A. Racine announced today that the District and 48 states have reached a $71 million consumer protection settlement with pharmaceutical manufacturer Amgen Inc. to resolve allegations that Amgen unlawfully promoted its drugs Aranesp and Enbrel. The settlement provides for a court injunction governing how Amgen markets drugs in the District.
Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat a number of conditions, including plaque psoriasis.